Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rocket Pharmaceuticals, Inc. - Common Stock (NQ:RCKT)

3.290 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 258
Open 3.290
Bid (Size) 3.170 (100)
Ask (Size) 3.490 (100)
Prev. Close 3.290
Today's Range 3.290 - 3.290
52wk Range 2.190 - 18.17
Shares Outstanding 65,837,894
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline. 
Via Benzinga
ROCKET ALERT: Bragar Eagel & Squire, P.C. is Investigating Rocket Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Performance

YTD
-74.1%
-74.1%
1 Month
+3.5%
+3.5%
3 Month
+8.2%
+8.2%
6 Month
-47.9%
-47.9%
1 Year
-80.4%
-80.4%

More News

Read More
FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock
Via Benzinga
Domino's Pizza Posts Upbeat Results, Joins Astria Therapeutics, Albertsons Companies, Polaris And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharma Stock Gets A Price Target Cut After Withdrawing FDA Application For Rare Bone Marrow Disorder Gene Therapy
Via Stocktwits
FDA Outlines Process To Speed Up Rare Disease Therapy Approvals
Via Benzinga
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Coty, Bilibili, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Why Nordson Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Which stocks are experiencing notable movement on Wednesday?
Via Chartmill
Citi Believes FDA May Closely Watch Sarepta’s Safeguards For Gene Therapy In Non-Ambulatory DMD Patients
Via Stocktwits
Topics Death
Traders are paying attention to the gapping stocks in Wednesday's session.
Via Chartmill
TJX Posts Better-Than-Expected Earnings, Joins Rocket Pharmaceuticals, Guess? And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy
Via Benzinga
Wednesday's pre-market session: top gainers and losers
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Is Rocket Pharma Stock Up 15% Pre-Market Today?
Via Stocktwits
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
From Faruqi & Faruqi, LLP
Via Business Wire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) Shareholders
Via TheNewswire.com
Topics Fraud Lawsuit
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) Shareholders
Via NewMediaWire
Topics Fraud Lawsuit
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT
From Pomerantz LLP
Via GlobeNewswire

Frequently Asked Questions

Is Rocket Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Rocket Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Rocket Pharmaceuticals, Inc. - Common Stock trade on?
Rocket Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Rocket Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Rocket Pharmaceuticals, Inc. - Common Stock is RCKT on the Nasdaq Stock Market
What is the current price of Rocket Pharmaceuticals, Inc. - Common Stock?
The current price of Rocket Pharmaceuticals, Inc. - Common Stock is 3.290
When was Rocket Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Rocket Pharmaceuticals, Inc. - Common Stock was at 11/04/25 04:00 PM ET
What is the market capitalization of Rocket Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Rocket Pharmaceuticals, Inc. - Common Stock is 216.61M
How many shares of Rocket Pharmaceuticals, Inc. - Common Stock are outstanding?
Rocket Pharmaceuticals, Inc. - Common Stock has 217M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.